ArticleACR open rheumatology2025
Use of
Article in ACR open rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Crosstalk between macrophages and fibroblasts contributes to inflammation and damage in giant cell arteritis.Rheumatology (Oxford, England) · 2026Article
- Scoping review of clinical, laboratory, histopathological and imaging predictors of relapse in adults with biopsy- or temporal artery ultrasound-confirmed giant cell arteritis on standard therapy with glucocorticoids alone or in combination with biologics.Rheumatology advances in practice · 2026Review
- The Role of FDG-PET in the Diagnosis and Monitoring of Large-Vessel Vasculitis.Current rheumatology reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveThe objective of this study was to assess the value of
methodsPatients with GCA were recruited into a prospective cohort in which they underwent clinical, laboratory, and imaging assessments, including FDG-PET. FDG-PET scans were interpreted as active or inactive based on global impression by two independent readers. The PET Vascular Activity Score (PETVAS) was calculated to quantify arterial FDG uptake (scale 0-27). Vascular FDG-PET findings were described in patients with GCA on tocilizumab for at least six months. For patients in established clinical remission, FDG-PET findings were compared between those treated with tocilizumab versus glucocorticoid monotherapy.
resultsA total of 36 patients with GCA underwent FDG-PET imaging on tocilizumab. Five patients had active clinical symptoms, and FDG-PET scans were active in all cases (PETVAS range: 20-27). For the 31 patients in clinical remission on tocilizumab, FDG-PET was active in 16 of these patients (52%) across a wide range of PETVAS (range 11-27). There were no associations between FDG-PET activity during remission and historical clinical features or longitudinal outcomes, including relapse risk or angiographic progression of disease. PETVAS was significantly lower during clinical remission in patients treated with tocilizumab compared to an additional 12 patients treated with glucocorticoid monotherapy (PETVAS 18 vs 24; P = 0.02).
conclusionFDG-PET has limited value to guide management decisions or inform prognosis when obtained during remission in patients with GCA on tocilizumab. Compared to glucocorticoid monotherapy, tocilizumab significantly reduces, but often does not eliminate, vascular inflammation in GCA.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.